Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 May-Jun;29(3):e13098.
doi: 10.1111/hel.13098.

Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial

Qingzhou Kong  1   2   3 , Iqtida Ahmed Mirza  1   2   3 , Xiaoqian Zhang  4 , Xiaohui Song  5 , Xiaowei Li  6 , Qiumei Zhang  7 , Lidong Xu  8 , Yuting Guo  9 , Yanan Yu  10 , Xiuli Zuo  1   2   3 , Yanqing Li  1   2   3 , Yueyue Li  1   2   3
Affiliations
Randomized Controlled Trial

Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial

Qingzhou Kong et al. Helicobacter. 2024 May-Jun.

Abstract

Background: Potassium-competitive acid blockers have demonstrated enormous potential in the eradication treatment of Helicobacter pylori infection, with tegoprazan being one of the representatives. The available data on the safety and efficacy of tegoprazan in dual therapy are limited.

Materials and methods: The multicenter, noninferiority, randomized-controlled trial was conducted from May 2023 to March 2024. Treatment-naive subjects were randomly assigned (1:1) to enter either the tegoprazan-amoxicillin (TA) group (tegoprazan 50 mg twice daily and amoxicillin 750 mg four times daily) or the esomeprazole-amoxicillin (EA) group (esomeprazole 20 mg and amoxicillin 750 mg all four times daily), with a duration for 14 days. The primary outcome was eradication rate as determined by 13C-urea breath test, including per-protocol (PP) analysis and intention-to-treat (ITT) analysis. Secondary outcomes were adverse events and compliance.

Results: A total of 368 individuals were included in the randomization. The eradication rates in the EA group and the TA group were 84.2% and 85.8%, respectively, according to an ITT analysis (p = 0.77), and 88.5% and 88.2%, respectively, according to PP analysis (p = 1.00). The eradication rates for the TA group were not inferior to those of the EA group in both PP (p = 0.0023) and ITT analyses (p = 0.0009). There were no significant statistical differences in the incidence of adverse events and compliance between the two groups. The multivariate logistic regression analysis revealed that poor compliance increased the risk of eradication failure (p < 0.001).

Conclusions: Dual therapy containing tegoprazan is safe and effective to be considered as a clinical first-line treatment option, but further optimization involving antimicrobial susceptibility testing and adjustments in dosage and frequency is warranted.

Trial registration: ClinicalTrials.gov ID: NCT05870683.

Keywords: Helicobacter pylori; efficacy; eradication; safety; tegoprazan.

PubMed Disclaimer

References

    1. A. P. Thrift, T. N. Wenker, and H. B. El‐Serag, “Global Burden of Gastric Cancer: Epidemiological Trends, Risk Factors, Screening and Prevention,” Nature Reviews Clinical Oncology 20 (2023): 338–349.
    1. P. Malfertheiner, F. Megraud, T. Rokkas, et al., “Management of Helicobacter pylori Infection: The Maastricht VI/Florence Consensus Report,” Gut 71 (2022): 1724–1762.
    1. P. Malfertheiner, M. C. Camargo, E. El‐Omar, et al., “Helicobacter pylori Infection,” Nature Reviews. Disease Primers 9 (2023): 19.
    1. S. F. Moss, S. C. Shah, M. C. Tan, and H. B. El‐Serag, “Evolving Concepts in Helicobacter pylori Management,” Gastroenterology 166 (2023): 267–283.
    1. X. Q. Wu, M. Duan, Q. Z. Kong, et al., “Clarifying Varied Helicobacter pylori Eradication Therapies: A Comprehensive Review,” Helicobacter 29 (2024): 15.

Publication types

MeSH terms

Associated data